Salarius Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance Amid Delisting Concerns
Salarius Pharmaceuticals Inc. has been granted an extension by the Nasdaq Hearings Panel to regain compliance with exchange listing requirements, specifically regarding their equity standards and minimum bid price. The extension is contingent upon Salarius meeting scheduled milestones, including regaining compliance with the equity standard by early July 2025 and the minimum bid price requirement by early August 2025. Previously, Salarius had received a notice about non-compliance due to their stock's closing bid price being below $1.00 per share for 30 consecutive business days. Following a hearing on June 3, 2025, Salarius is working towards achieving these milestones to maintain their listing on the Nasdaq Capital Market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001615219-25-000064), on June 16, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。